🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against superbug strains of the infection, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with figures suggesting over 82 million infections annually. Particularly high rates are seen in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the highly restricted available drugs at this time.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, also known as a brand name, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, gained clearance in the same week. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This approval represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Outcomes and Worldwide Availability

According to findings detailed in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which combines a dual-drug approach. The trial included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in a wide range of regions with limited resources.

Doctors treating patients have shared hope. The availability of a single-dose, oral treatment like this is described as a "revolutionary step" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.